Biotinylated Recombinant Human Mesothelin (MSLN) Protein (hFc-Avi)

Name: Biotinylated Recombinant Human Mesothelin (MSLN) Protein (hFc-Avi)
Brand: Beta LifeScience
SKU: BLC-06334P
Price: 240.0 USD
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Avi-tagged proteins, Back to school. back to lab. ready for results. - advance your research with beta lifescience, Biotinylated proteins, Car-nk targets proteins, Featured biotinylated protein molecules, High-quality recombinant proteins, In-stock recombinant proteins, Recombinant cell therapy targets for car-t research

Price Save $356

Size

100ug

Quantity

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Biotinylated Recombinant Human Mesothelin (MSLN) Protein (hFc-Avi) is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q13421
Target Symbol	MSLN
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	N-hFc-Avi
Target Protein Sequence	EVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQG
Expression Range	296-580aa
Protein Length	Partial of Isoform 3
Mol. Weight	61.4 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Membrane-anchored forms may play a role in cellular adhesion.; Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
Subcellular Location	Cell membrane; Lipid-anchor, GPI-anchor. Golgi apparatus.; [Megakaryocyte-potentiating factor]: Secreted.; [Isoform 3]: Secreted.
Protein Families	Mesothelin family
Database References	HGNC: 7371 OMIM: 601051 KEGG: hsa:10232 STRING: 9606.ENSP00000372313 UniGene: PMID: 30319054 We have demonstrated that a rising serum mesothelin is a sensitive marker of progression in the follow up of patients with MPM. PMID: 29454314 we engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold to bind to mesothelin with high affinity, using directed evolution and yeast surface display PMID: 29738555 Our goal was to stimulate antitumor immunity by combining SS1P or LMB-100 with anti-CTLA-4. We constructed a BALB/c breast cancer cell line expressing human mesothelin (66C14-M), which was implanted in one or two locations. SS1P or LMB-100 was injected directly into established tumors and anti-CTLA-4 administered i.p. In mice with two tumors, one tumor was injected with immunotoxin and the other was not. PMID: 28674083 Mesothelin-targeted immunotoxin RG7787 increases pancreatic cancer cell sensitivity to taxane-mediated killing by increasing taxane-mediated microtubule stability and priming cells for apoptosis by decreasing levels of the pro-survival factor Mcl-1. PMID: 27999204 RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response. These results indicate that this combination could be useful for treating patients with mesothelioma PMID: 27635089 Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. PMID: 28929447 Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.( PMID: 28287406 MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth. PMID: 28125734 we report herein that high tumor mesothelin expression predicts a shorter PFS and OS in EOC patients and demonstrates that serum mesothelin predicts local tumor mesothelin expression. PMID: 28160193 We provide new evidence for the role of MSLN in EMT regulation, tumorigenesis and metastasis. Knockdown of MSLN led to mesenchymal to epithelial transition and less aggressive behavior of lung carcinoma and mesothelioma cells. PMID: 28288645 MSLN expression increases cell migration and invasion in vitro. PMID: 27422997 SMRP but not FBLN3 has a role in pleural effusions in in malignant pleural mesothelioma PMID: 28314308 High mesothelin expression is associated with malignant pleural mesothelioma. PMID: 27646775 Calretinin, D2-40 and mesothelin are aberrantly expressed in a proportion of CRC cases. PMID: 27062033 Our results showed that IMP3 immunostaining has a higher sensitivity and specificity than mesothelin for the diagnosis of pancreatic ductal adenocarcinoma. IMP3 and mesothelin may be useful markers in distinguishing neoplastic from reactive lesions of the pancreas in instances where this is impossible by morphology alone in surgical pathology practice. PMID: 26874572 Results indicate a specific mesothelin-driven tumor uptake of targeted 89zirconium-labeled antibody which visualizes mesothelin expressing pancreatic cancer in real time. PMID: 26536664 Data indicate that triple-negative breast cancer (TNBC) showed the highest amplification rate (42%) in the basal-like 1 subtype. PMID: 26172299 There was a trend toward elevation of SMRP values in healthy individuals exposed to asbestos compared to those without exposure. Within asbestosis cases, those with higher profusion scores had higher SMRP values than those with lower profusion scores. PMID: 26188910 High mesothelin expression was strongly associated with mutant KRAS/wild-type EGFR and poor prognosis in advanced lung cancer. PMID: 26028668 findings replicate association between rs1057147 and soluble mesothelin related peptide(SMRP)levels; SMRP performance as diagnostic biomarker for malignant pleural mesothelioma improved by considering genotype rs1057147; this polymorphism most likely affects a binding site for miR-611 PMID: 25436799 Expression of mesothelin was observed in 42.3% of patients with triple negative breast cancer. PMID: 25776500 Patients with mesothelin-positive triple negative breast carcinomas (TNBC) were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. PMID: 25506917 Delivery of mesothelin-targeted CAR T cells eradicates tumors in mice with pleural malignancies. PMID: 25378643 Pleural fluid mesothelin may serve as a marker for pleural malignant mesothelioma. PMID: 25505814 Patients with colon cancer had significantly higher mesothelin serum levels than the control groups. PMID: 25477701 Mesothelin expression is associated with poor outcomes in breast cancer.Mesothelin is a prognostic breast tumor marker whose expression is highly enriched in triple negative breast cancer tumors. PMID: 25193277 A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. PMID: 25227779 Both the serum CA125(meso) level and the ratio of the serum CA125(mesothelin) to CA125 levels (CA125(mesothelin) /CA125) were significantly higher in patients with EOC. PMID: 25197000 Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID: 24308545 MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. PMID: 24465798 Being negative/focally positive for mesothelin expression was associated with longer postoperative survival than positive expression in patients with cholangiocellular carcinoma. Mesothelin positivity was a predictor of short postoperative survival. PMID: 23701154 Our findings suggest that MLSN can be used as a marker of neoplastic transformation of epithelial cells in pancreatic mucinous cysts. PMID: 25125620 MSLN expression in patients with early-stage lung adenocarcinoma is associated with increased risk of recurrence and reduced overall survival. PMID: 24334761 These data provides evidence for the use of mesothelin as an immunogen for tumour-specific T cell response. PMID: 24520352 Mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. PMID: 23512344 In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer. PMID: 24146039 Use of S100P and mesothelin in cytologically borderline cases can increase the diagnostic accuracy for pancreatic adenocarcinoma. PMID: 21538952 Data indicate that biochemical markers significantly associated with mesothelioma were hyaluronan, N-ERC/mesothelin and syndecan-1. PMID: 23991032 PE-SMRP adds some clinical information in the work-up of patients with a PE of unknown origin. PMID: 23873013 Mesothelin expression was identified in 34% of patients with triple receptor negative breast cancer. PMID: 23810431 addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with multiple myeloma PMID: 24324091 These data suggest that in difficult diagnostic cases both PAX2 and mesothelin immunohistochemical study may be useful in discriminating between PMRCC and primary pancreatic carcinoma. PMID: 24344503 SMRP could improve CYFRA 21-1 antigen and carcinoembryonic antigen (CEA) accuracy in the differential diagnosis of malignant pleural mesothelioma. PMID: 23532816 Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. PMID: 23694968 Mesothelin, megakaryocyte potentiating factor and osteopontin are expressed in malignant mesothelioma [review] PMID: 22835614 MSLN overexpression promoted the invasive potential of MCF-7 cells through ERK1/2-dependent upregulation of MMP-9; this association may have contributed to metastasis of MCF-7 cells in vivo. PMID: 23321167 Data indicate that binding of mesothelin to CA125 does not alter the measurement of mesothelin for the detection of malignant mesothelioma (MM). PMID: 23357461 The mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide. PMID: 22721387 SMRP was lower in healthy subjects than in subjects with malignant tumors, asbestos-related pleural lesions, and other benign diseases PMID: 23277285

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.